Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 14.37 3.83% 0.53
APLS closed up 3.83 percent on Tuesday, February 19, 2019, on 59 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical APLS trend table...

Date Alert Name Type % Chg
Feb 19 Bollinger Band Squeeze Range Contraction 0.00%
Feb 19 BB Squeeze Started Range Contraction 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 15 20 DMA Support Bullish 3.83%
Feb 15 Outside Day Range Expansion 3.83%
Feb 14 Stochastic Reached Overbought Strength 1.13%
Feb 14 Weak + Overbought Other 1.13%
Feb 14 Overbought Stochastic Strength 1.13%
Feb 12 Crossed Above 20 DMA Bullish 0.00%
Feb 11 Fell Below 20 DMA Bearish 4.74%

Older signals for APLS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
Is APLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 11.45
Average Volume 292,800
200-Day Moving Average 17.5036
50-Day Moving Average 14.5398
20-Day Moving Average 13.6075
10-Day Moving Average 13.847
Average True Range 0.84
ADX 10.52
+DI 17.9386
-DI 18.1504
Chandelier Exit (Long, 3 ATRs ) 12.65
Chandelier Exit (Short, 3 ATRs ) 15.02
Upper Bollinger Band 14.5093
Lower Bollinger Band 12.7057
Percent B (%b) 0.92
BandWidth 13.254455
MACD Line -0.0399
MACD Signal Line -0.1744
MACD Histogram 0.1345
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.53
Resistance 3 (R3) 15.43 14.96 15.33
Resistance 2 (R2) 14.96 14.66 15.00 15.27
Resistance 1 (R1) 14.66 14.48 14.81 14.76 15.20
Pivot Point 14.19 14.19 14.26 14.23 14.19
Support 1 (S1) 13.89 13.89 14.04 13.99 13.54
Support 2 (S2) 13.42 13.71 13.46 13.47
Support 3 (S3) 13.12 13.42 13.41
Support 4 (S4) 13.22